Structural Basis of BRCC36 Function in DNA Repair and Immune Regulation by Rabl, Julius et al.
u n i ve r s i t y  o f  co pe n h ag e n  
Københavns Universitet
Structural Basis of BRCC36 Function in DNA Repair and Immune Regulation
Rabl, Julius; Bunker, Richard D; Schenk, Andreas D; Cavadini, Simone; Gill, Mark E;
Abdulrahman, Wassim; Andrés-Pons, Amparo; Luijsterburg, Martijn S; Ibrahim, Adel F M;
Branigan, Emma; Aguirre, Jacob D; Marceau, Aimee H; Guérillon, Claire; Bouwmeester,
Tewis; Hassiepen, Ulrich; Peters, Antoine H F M; Renatus, Martin; Gelman, Laurent; Rubin,
Seth M; Mailand, Niels; van Attikum, Haico; Hay, Ronald T.; Thomä, Nicolas H
Published in:
Molecular Cell
DOI:
10.1016/j.molcel.2019.06.002
Publication date:
2019
Document version
Publisher's PDF, also known as Version of record
Document license:
CC BY-NC-ND
Citation for published version (APA):
Rabl, J., Bunker, R. D., Schenk, A. D., Cavadini, S., Gill, M. E., Abdulrahman, W., ... Thomä, N. H. (2019).
Structural Basis of BRCC36 Function in DNA Repair and Immune Regulation. Molecular Cell, 75(3), 483-497.e9.
https://doi.org/10.1016/j.molcel.2019.06.002
Download date: 03. Feb. 2020
ArticleStructural Basis of BRCC36 Function in DNA Repair
and Immune RegulationGraphical AbstractHighlightsd Detailed structural studies of the BRCA1-A and BRISC-
SHMT2 protein complex
d Complex-specific subunits functionalize BRCC36, regulating
its activity and targeting
d BRCA1-A sequesters BRCA1 with nanomolar affinity
d Cancer-associated metabolic enzyme SHMT2 inhibits BRISC
deubiquitination activityRabl et al., 2019, Molecular Cell 75, 483–497
August 8, 2019 ª 2019 The Authors. Published by Elsevier Inc.
https://doi.org/10.1016/j.molcel.2019.06.002Authors
Julius Rabl, Richard D. Bunker,
Andreas D. Schenk, ...,
Haico van Attikum, Ronald T. Hay,
Nicolas H. Thom€a
Correspondence
nicolas.thoma@fmi.ch
In Brief
Structural studies of the BRCA1-A and
BRISC complexes reveal a common
enzymatic core that is functionalized by
complex-specific proteins. BRCA1-A
localizes to DNA double-strand breaks,
sequesters BRCA1, and suppresses DNA
resection. BRISC regulates protein
degradation by the endosomal-lysosomal
pathway through deubiquitination and is
inhibited by the metabolic
enzyme SHMT2.
Molecular Cell
ArticleStructural Basis of BRCC36 Function
in DNA Repair and Immune Regulation
Julius Rabl,1,2,8 Richard D. Bunker,1,2 Andreas D. Schenk,1,2 Simone Cavadini,1,2 Mark E. Gill,1,2
Wassim Abdulrahman,1,2,9 Amparo Andre´s-Pons,1,2 Martijn S. Luijsterburg,3 Adel F.M. Ibrahim,6 Emma Branigan,6
Jacob D. Aguirre,1,2 Aimee H. Marceau,4 Claire Gue´rillon,5 Tewis Bouwmeester,7 Ulrich Hassiepen,7
Antoine H.F.M. Peters,1,2 Martin Renatus,7 Laurent Gelman,1,2 Seth M. Rubin,4 Niels Mailand,5 Haico van Attikum,3
Ronald T. Hay,6 and Nicolas H. Thom€a1,2,10,*
1Friedrich Miescher Institute for Biomedical Research, Maulbeerstrasse 66, 4058 Basel, Switzerland
2University of Basel, Petersplatz 10, 4003 Basel, Switzerland
3Leiden University Medical Center, Department of Human Genetics, Einthovenweg 20, 2333 ZC Leiden, the Netherlands
4Department of Chemistry and Biochemistry, University of California, Santa Cruz, CA, USA
5Novo Nordisk Foundation Center for Protein Research, University of Copenhagen, Blegdamsvej 3b, 2200 Copenhagen N, Denmark
6Centre for Gene Regulation and Expression, Sir James Black Centre, School of Life Sciences, University of Dundee, Dow Street, Dundee,
DD1 5EH, UK
7Novartis Institutes for BioMedical Research, Novartis Pharma AG, 4002 Basel, Switzerland
8Present address: Scientific Center for Optical and Electron Microscopy (ScopeM), ETH Z€urich, 8093 Z€urich, Switzerland
9Present address: leadXpro AG, PARK innovAARE, 5234 Villigen, Switzerland
10Lead Contact
*Correspondence: nicolas.thoma@fmi.ch
https://doi.org/10.1016/j.molcel.2019.06.002SUMMARY
In mammals, 100 deubiquitinases act on 20,000
intracellular ubiquitination sites. Deubiquitinases
are commonly regarded as constitutively active,
with limited regulatory and targeting capacity. The
BRCA1-A and BRISC complexes serve in DNA dou-
ble-strand break repair and immune signaling and
contain the lysine-63 linkage-specific BRCC36 sub-
unit that is functionalized by scaffold subunits
ABRAXAS and ABRO1, respectively. The molecular
basis underlying BRCA1-A and BRISC function is
currently unknown. Here we show that in the
BRCA1-A complex structure, ABRAXAS integrates
the DNA repair protein RAP80 and provides a high-
affinity binding site that sequesters the tumor sup-
pressor BRCA1 away from the break site. In the
BRISC structure, ABRO1 binds SHMT2a, ametabolic
enzyme enabling cancer growth in hypoxic environ-
ments, which we find prevents BRCC36 from binding
and cleaving ubiquitin chains. Our work explains
modularity in the BRCC36 DUB family, with different
adaptor subunits conferring diversified targeting and
regulatory functions.
INTRODUCTION
The deubiquitinase (DUB) BRCC36 is the catalytic subunit for
two multi-protein complexes: BRCA1-A, which safeguards
genome integrity by regulating DNA repair pathway choice,
and BRISC, which serves cellular stress response and immuneMolecular Cell 75, 483–497, A
This is an open access article under the CC BY-Nsignaling functions (Wu et al., 2012; Yin et al., 2012; Zheng
et al., 2013). Both BRCC36-containing complexes are specific
for lysine-63-linked ubiquitin (K63-Ub) chains (Cooper et al.,
2009; Zeqiraj et al., 2015). BRCA1-A and BRISC also contain
proteins MERIT40 (Feng et al., 2009; Shao et al., 2009; Wang
et al., 2009) and BRE (Feng et al., 2009; Hu et al., 2011a) as
core components. The key compositional differences between
the two complexes are the two scaffolding partners of
BRCC36 (Figure S1A): in BRCA1-A, BRCC36 is supported by
ABRAXAS (Wang et al., 2007), whereas in BRISC, it is paired
with ABRO1 (Hu et al., 2011a; Wang et al., 2007). ABRAXAS
and ABRO1 are evolutionarily related as they share 30% iden-
tity in humans and contain Mpr1, Pad1 N-terminal (MPN) do-
mains like BRCC36 (Figures S1B and S1C).
BRCA1 and BRCA2 facilitate DNA double-strand break (DSB)
repair by homologous recombination (HR), whereas BRCA1-A
opposes HR by suppressing resection (Coleman andGreenberg,
2011; Hu et al., 2011b). The BRCA1-A assembly constitutively in-
cludes the repair protein RAP80 (Kim et al., 2007; Sobhian et al.,
2007; Wang et al., 2007), a protein that recognizes K63-Ub chro-
matin domains generated by ɣ-H2AX-dependent DNA damage
signaling through RNF4/RNF8/RNF168 (Guzzo et al., 2012;
Typas et al., 2015; Uckelmann and Sixma, 2017).
Familial mutations in the BRCA1-A proteins ABRAXAS and
RAP80 predispose carriers to early-onset breast cancer, analo-
gous tomutations inBRCA1 andBRCA2 (Nikkil€a et al., 2009; Sol-
yom et al., 2012). BRCA1-A requires the tandem ubiquitin (UIM2)-
and SUMO-interacting motifs (SIM) in RAP80 and the BRCC36
DUB to function in DNA repair (Guzzo et al., 2012; Hu et al.,
2012; Lombardi et al., 2017; Ng et al., 2016). BRCA1-A recruits
BRCA1 by binding its BRCT domains upon phosphorylation of
a motif near the C terminus of ABRAXAS (Wang et al., 2007).
BRCA1 binding to BRCA1-A sequesters the HR activator
BRCA1 2–10 kb distal from DNA break sites (Goldstein andugust 8, 2019 ª 2019 The Authors. Published by Elsevier Inc. 483
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Kastan, 2015; Kakarougkas et al., 2013), which is posited to limit
HR (Goldstein and Kastan, 2015). It is currently unclear how
BRCA1-A is functionalized and targetedbyRAP80 andABRAXAS
and how BRCA1 is inhibited when bound to the complex.
While BRCA1-A is predominantly confined to the nucleus,
BRISC localizes to the nucleus and the cytoplasm, where its
wide range of reported substrates includes ATF4, THAP5,
NLRP3, and the cytosolic domain of IFNAR1, an interferon re-
ceptor (Ambivero et al., 2012; Cilenti et al., 2011; Py et al.,
2013; Zheng et al., 2013). BRISC has been noted to co-purify
with serine hydroxy methyltransferase 2 (SHMT2), a metabolic
enzyme that converts serine to glycine and a tetrahydrofolate-
bound one-carbon unit, and occurs in cytosolic (SHMT2a) and
mitochondrial (mSHMT2) forms (Giardina et al., 2015; Sowa
et al., 2009; Zheng et al., 2013). SHMT2 is implicated in regu-
lating two medically important aspects of BRISC function, inter-
feron signaling, and viral protein degradation (Xu et al., 2018;
Zheng et al., 2013). Since overexpression of SHMT2 plays a
pivotal role in themetabolic adaptation of cancer cells to hypoxia
(Kim et al., 2015; Lee et al., 2014; Sowa et al., 2009; Zheng et al.,
2013), we aimed to understand the functional interplay between
BRISC and SHMT2.
While some DUBs have specificity for cleaving distinct ubiqui-
tin-chain linkages, they are not typically regarded as modular,
multimeric enzymes and are not assumed to exhibit specificity
for individual proteins or pathways. The available data for the
BRISC and BRCA1-A complexes, however, suggested that a
shared DUB core might assume different roles in DNA repair
and immune signaling. To examine the mechanistic circuitry in
these multimeric DUB assemblies, we set out to study the mo-
lecular basis of BRCA1-A and BRISC regulation and targeting.
RESULTS
Common Architectural Cores of the BRCA1-A and
BRISC Assemblies
We determined the structure of the 10-protein mouse BRCA1-A
complex (overall molecular weight of 338 kDa; highly similar to
human BRCA1-A), comprising two copies each of BRCC36,
ABRAXAS, BRE, MERIT40, and RAP80 (residues 274–334) by
X-ray crystallography using low-resolution native Zn-SAD
phasing methods and carried out final refinement at 3.75 A˚ res-
olution (Figures 1A and 1B; Figure S1D; Table 1). In addition, we
characterized the structure of the 10-protein human BRISC-
SHMT2a complex (overall molecular weight 445 kDa) by cryoe-
lectron microscopy (cryo-EM) at an overall resolution of 3.86 A˚
(Figures 1B and 1C; Figures S1D, S2A–S2E; Table 2). Analogous
to BRCA1-A, the BRISC structure comprises two copies each of
proteins BRCC36, ABRO1, BRE, MERIT40, and SHMT2a. We
used the A264T mutant of SHMT2a (A285T in mSHMT2) for all
structural studies and biochemical characterization, which was
originally used to solve the crystal structure of the dimeric apo-
SHMT2 (PDB: 6DK3). SHMT2 residue numbers in the text refer
to SHMT2a.
In BRCA1-A, two heteropentamers composed of BRCC36,
ABRAXAS, BRE, and MERIT40 form an arc-shaped complex
with approximate dimensions 213 3 117 3 87 A˚3 (Figure 1A).
The two half-arcs contact each other through BRCC36 and its484 Molecular Cell 75, 483–497, August 8, 2019scaffold partner ABRAXAS. While BRCC36 and ABRAXAS
both contain MPN domains, only that of BRCC36 is catalytically
active (Figure S3A). In our crystals, the BRCC36 catalytic center
is captured in an active configuration, with a single catalytic Zn2+
ion tetrahedrally coordinated by His122, His124, Asp135, and a
water molecule, oriented by Glu33 (Zeqiraj et al., 2015) (Fig-
ure S3A). We find that BRCC36 in BRCA1-A and BRISC is acti-
vated by assembly due to interaction between Glu30 of
BRCC36 and Asn170 in ABRAXAS and Asn164 in ABRO1,
respectively, which structures the activation loop and positions
the catalytic Glu33 (Figure S3B). This mechanism is homologous
to what has been observed in the ancestral BRCC36-KIAA0157
complex (Zeqiraj et al., 2015) but is distinct from that seen in the
COP9 signalosome (CSN) and the proteasome lid, where the po-
sition of the scaffold MPN domain differs (Figure S3B) (Lingaraju
et al., 2014; Pathare et al., 2014; Worden et al., 2014, 2017).
In the BRCA1-A complex structure, the ABRAXAS MPN
domain plays a key structural role connecting the catalytically
active BRCC36 subunit to the distal part of the arc consisting of
BRE, MERIT40, and RAP80 (Figure 1A). BRE, in turn, forms the
central bridge between the ABRAXAS-BRCC36 MPN domain
dimer and the Von-Willebrand factor A (VWA) domain protein
MERIT40 (Figures 1A and 2A). BRE contains N- and C-terminal
ubiquitin E2 variant (UEV) domains (Figure 2A). We identify a
new, third domain in BRE, a previously unidentified central
RING-finger containing, WD-repeat-containing proteins and
yeastDEAD (DEXD)-like helicasedomain (RWD) locatedbetween
theUEVdomains (Figures 1Band 2A; Figure S3C). TheBRERWD
andC-terminal UEV (UEV-C) domains are connected by a contin-
uous helix, similar to the arrangement of the UEV and RWD
domain observed in human DNA repair protein FANCL (Hodson
et al., 2011) (Figure S3D). The BRE N-terminal UEV
domain (UEV-N) binds the ABRAXAS MPN domain, and the
BREUEV-CholdsMERIT40 at the extremity of the arc (Figure 2A).
In the BRCA1-A complex, the two heteropentamers are inti-
mately linked by a bundle of four ⍺helices comprising the C-ter-
minal tails of BRCC36 and ABRAXAS (Figure 1A; Figure S3E). An
ABRAXAS linker segment and an a helix crossover from one site
of the half-arc to the other effectively interlock the two pentamers
(Figure S3E). The same arrangement is found in BRISC (Fig-
ure S3E). This crossover arrangement is not observed in the
ancestral BRCC36/KIAA0157 subcomplex (Figure S3E), where
dissociation of the two pentamers has been suggested as a pu-
tative mechanism to regulate activity (Zeqiraj et al., 2015). Given
the observed pseudo-knotted arrangement, regulation by disso-
ciation is unlikely in the case of mammalian BRCA1-A, and
instead, we find that accessory subunits, such as RAP80, have
appeared in the evolutionary lineage to confer targeting and reg-
ulatory capabilities.
The BRCA1-A/BRISC Architecture Offers a Scaffold for
Ubiquitin Binding
In light of themultipleubiquitin-bindingmodules inBRE,we tested
BRCA1-A with K63-linked chains of different length ranging from
di-ubiquitin (Ub)2 and tri-ubiquitin (Ub)3 to tetra-ubiquitin (Ub)4.
BRE contains UEV/RWD binding domains, with a K63-linked
ubiquitin-binding site previously reported for the BRE-MERIT40
complex (Kyrieleis et al., 2016). We saw preferential cleavage of
Figure 1. Structures of the BRCA1-A and BRISC-SHMT2a Complexes
(A) A cartoon representation of the BRCA1-A complex crystal structure.
(B) Schematic representation of the domain boundaries of BRCA1-A and BRISC-SHMT2a, showing parts present in the structure (domain cartoons and solid
line), parts that are present in the construct but disordered in the structure (dashed line), and parts not present in the construct (grayed out domain cartoons and
solid gray line).
(C) A cartoon representation of the BRISC-SHMT2a complex cryo-EM structure.(Ub)4, while no cleavage of (Ub)2 and (Ub)3 chains was observed
under these conditions (Figure 2B). BRISC similarly exhibited
preferential cleavage for longer chains (Figure S3F). Cleavage of
(Ub)2, however, was seen when reactions were run at higher tem-
peratures and enzyme concentrations (Figure S3G). (Ub)4 units
span 90 A˚ and may thus connect the BRCC36 active site to
BRE and potentially MERIT40. In light of the structure, we tested
whether the VWA domain of the distal MERIT40 itself also poten-
tially contributed to ubiquitin binding. NMR binding studies
using 15N-labeled ubiquitin found mono-ubiquitin binding to
BRE-MERIT40 complex with estimated micromolar affinity (Fig-
ure S3H). Additionally, the isolated MERIT40 subunit bound
ubiquitin with estimated high micromolar affinity (Figure S3H),comparable to established ubiquitin-binding domains (Hicke
et al., 2005). The arc-shaped BRCA1-A/BRISC architecture thus
offers a ubiquitin-binding scaffold potentially ranging from the
BRCC36 active site located at the middle of the arc up to the
MERIT40 subunits located at the tip.
We then tested whether this arrangement pre-orientates the
(Ub)4 chains for cleavage or whether the ubiquitin-binding mod-
ules predominately serve to generate high local concentrations.
For this, we introduced fluorescent labels on either the proximal
or the distal end of (Ub)4 chains (Figure 2C). Incubating the prox-
imally labeled substrate with BRCA1-A, we mostly observed
(Ub)2 and (Ub)3 cleavage products, while the distally labeled
sample resulted in a different cutting pattern, accumulatingMolecular Cell 75, 483–497, August 8, 2019 485
Table 1. BRCA1-A Crystallographic Data Collection and
Refinement Statistics
Native Zn-SAD PDB: 6GVWa
Data Collection
Space group P212121 P212121
Cell dimensions
a, b, c (A˚) 97.07, 122.71,
431.94
97.10, 112.64,
431.33
Resolution (A˚) 118–4.30
(4.374–4.300)b
30–3.75
(3.814–3.750)
Rmeas 0.217 (>3.000) 0.175 (>3.000)
Rpim 0.024 (1.814) 0.025 (2.173)
CC1/2 0.999 (0.305) 0.952 (0.476)
Mean I/sI 18.3 (0.5) 11.6 (0.4)
Multiplicity 79.6 (79.1) 51.9 (52.8)
Completeness (%)
Spherical 100 (100) 100 (100)
Ellipsoidal – 82.6 (33.2)c
Refinement
Resolution (A˚) – 30–3.75
No. reflections – 42,193
Rwork/Rfree (%) – 22.72/25.91
No. atoms
Protein – 20,138
Zn2+ ions – 2
Water – 2
B factors
Protein – 229
Zn2+ ions – 193
Water – 163
RMSDs
Bond lengths (A˚) – 0.006
Bond angles () – 1.147
aData from 7 crystals were combined
bValues in parentheses are for highest-resolution shell
cAfter anisotropic truncation with STARANISO as used for refinement
Table 2. Cryo-EM Data Collection, Refinement, and Validation
Statistics
BRISC-SHMT2 (EMDB:
EMDB-0132; PDB: 6H3C)
Data Collection and Processing
Magnification 58,140
Voltage (kV) 300
Electron exposure (e–/A˚2) 45
Defocus range (mm) 0.5 to 5
Pixel size (A˚) 0.86
Symmetry imposed C2
Initial particle images (no.) 332,598
Final particle images (no.) 35,595
Map resolution (A˚) 3.86
FSC threshold 0.143
Map resolution range (A˚) 3.86–15
Refinement
Initial model used (PDB code) BRCA1-A (PDB: 6GVW),
SHMT2 (PDB: 5V7I)
Model resolution (A˚) 3.86
FSC threshold 0.143
Map sharpening B factor (A˚2) N/A
Model composition
Non-hydrogen atoms 25,134
Protein residues 3,154
Water 2
B factors (A˚2)
Protein 90.25
Water 64.48
RMSDs
Bond lengths (A˚) 0.020
Bond angles () 1.93
Validation
MolProbity score 1.32
Clashscore 1.88
Poor rotamers (%) 0.07
Ramachandran plot
Favored (%) 94.56
Allowed (%) 4.8
Disallowed (%) 0.64predominantly Ub cleavage products (Figure 2C). These findings
are consistent with alignment of the (Ub)4 chain with the distal
ubiquitin, pointing toward BRCC36, being cleaved first, in a pro-
cess likely supported by the multiple ubiquitin-binding domains
on BRE and MERIT40.
BRCA1-A RAP80 Integration
BRCA1-A activity in DNA repair critically depends on the pres-
ence of RAP80. Our crystal structure now demonstrates how
the RAP80 subunit functionalizes the complex. We find that the
RAP80 protein is solubilized and stabilized by the presence of
BRCA1-A and stably maintained in all purification steps. Our
BRCA1-A structure reveals that RAP80 is deeply integrated
into the BRCA1-A assembly by interactions with three subunits:
ABRAXAS, BRE, andMERIT40 (Figures 1A and 2A). The N-termi-
nal portion (Gly272-Trp278) of the RAP80 ABRAXAS-interacting486 Molecular Cell 75, 483–497, August 8, 2019region (AIR) engages MERIT40, the trailing ⍺ helix (Asn290-
Leu314) binds across the BRE UEV-C domain, with the RAP80
C terminus forming a b strand (Val315-Phe330) sandwiched by
the RWD andUEV-N domains of BRE. The ABRAXASC terminus
binds the ⍺ helix of RAP80 AIR through an ⍺-helical domain
(Ile277-Phe287), and the RAP80 AIR b sheet stacks in-between
b sheets fromMERIT40 and ABRAXAS (Figure 2A). The structural
elements of RAP80 AIR are highly conserved (Figure S4A).
While the region in RAP80 that mediates BRCA1-A binding is
short, it is essential for BRCA1-A function (Figures S4B–S4D).
It also gives rise to a relatively large interface between RAP80
Figure 2. Integration of RAP80 and DUB Specificity of BRCA1-A
(A) The position of the UEV-N, RWD, and UEV-C domains of BRE and the VWA domain of MERIT40 (shown as cartoon) within the BRCA1-A complex (shown as
surface). RAP80 is embedded into the complex through contacts with BRE, MERIT40, and ABRAXAS.
(B) BRCA1-A complex processes (Ub)4 faster than (Ub)3 and (Ub)2. K63-linked ubiquitin substrate (150 ng/lane) was incubated with 5 nM BRCA1-A on ice and
analyzed by silver-stained SDS-PAGE. Under these conditions, (Ub)4 is cleaved within 5 min, whereas (Ub)2 and (Ub)3 are not cleaved within 7 h.
(C) Tetra-ubiquitin chains are pre-oriented on BRCA1-A complex during cleavage, as evident from comparison of the degradation of K63-linked (Ub)4 substrate
labeled with TAMRA at the proximal and distal ubiquitin, respectively. Degradation products of 1 mM substrate incubated with 10 nM BRCA1-A at room tem-
perature were resolved on an SDS-PAGE; TAMRA was subsequently visualized.and BRE (1,951 A˚2 buried surface area) and MERIT40 (822 A˚2). It
is the interaction with ABRAXAS (1,146 A˚2), however, that drives
specific incorporation of RAP80 into BRCA1-A: while BRISC
alone integrates co-expressed RAP80 substoichiometrically
(Figure S4E), a hybrid BRISC complex that contains a fusion
scaffold protein, in which the C-terminal tail of ABRO1 (261–
415) is exchanged for that of ABRAXAS (269–407), tightly inte-
grates RAP80 (Figure 3A). The BRCA1-A-specific ABRAXAS
subunit drives RAP80 integration, while the BRE/MERIT40 sub-
units present in both BRISC/BRCA1-A complexes play an impor-
tant accessory role. Since BRISC and RAP80 are targeted to
different cellular compartments, association between BRISC
and RAP80 is not observed in vivo despite the presence of
BRE and MERIT40 (Feng et al., 2010).
Our structure of BRCA1-A explains the observation that loss of
BRE, or MERIT40, significantly impairs BRCA1-A function, re-
sulting in DNA repair defects and loss of cancer suppressionsimilar to what was seen for loss of RAP80 (Feng et al., 2009;
Hu et al., 2011a; Patterson-Fortin et al., 2010; Rebbeck et al.,
2011; Shao et al., 2009). The high degree of structural interde-
pendence between RAP80, BRE, and MERIT40 means that the
physical link between RAP80 and ABRAXAS, which is essential
for DNA repair, can no longer be efficiently retained in BRCA1-
A once BRE (accounts for 50% of the RAP80 interface) or
MERIT40 (accounts for 20%) is lost.
RAP80 binding further affects the BRCA1-A quaternary struc-
ture. A previous 20 A˚ low-resolution structure of truncated
BRCA1-A determined in the absence of RAP80 and using chem-
ical crosslinking reported the dimerization of two full BRCA1-A
arcs (Kyrieleis et al., 2016). We find that BRISC in the absence
of SHMT2 exists in an equilibrium between single arc and dimer,
which can be shifted toward the dimer by chemical crosslinking,
analogous to truncated BRCA1-A without RAP80 (Figures 3A
and 3B; Figures S4F and S4G). We observe a single arc ofMolecular Cell 75, 483–497, August 8, 2019 487
Figure 3. RAP80 Controls BRE Conformation
and Prevents Dimerization
(A) A fusion scaffold protein containing residues
1–260 of mouse ABRO1 fused to residues 269–407
of mouse ABRAXAS disrupts dimerization (native
PAGE) and integrates RAP80 stoichiometrically into
the complex (SDS-PAGE).
(B) The structure of BRISC dimer. A pseudoatomic
model of BRISC was generated by rigid-body fitting
of the atomic BRISC model derived from the cryo-
EM structure determination of BRISC-SHMT2a
complex into the density map of BRISC dimer.
(C) Integration of RAP80 into BRCA1-A results in a
substantial conformation change of BRE as evi-
denced by a comparison of the structures of
BRCA1-A and BRISC.RAP80-bound BRCA1-A in our crystal structure (Figure 1A) and
in negative-stain EM studies, irrespective of the use of chemical
crosslinking (Figure S4H). The presence of RAP80 binding re-
sults in a structural change in BRE and MERIT40, which in turn
prevents dimerization of the two arcs (Figure 3C; Figure S4I).
RAP80 is essential for BRCA1-A complex assembly and stability
in vivo (Bian et al., 2012), and its cellular concentration exceeds
that of ABRAXAS (Mok and Henderson, 2012). This, together
with the observed intricate structural integration of RAP80 into
BRCA1-A, suggests that RAP80 is a constitutive member of
the BRCA1-A complex and that the single arc observed in our
structure likely depicts the physiological assembly.
SUMO-Dependent Targeting of BRCA1-A
The RAP80 N-terminal region contains SIM (residues 41–43) and
K63-linkage- specific tandem UIM domains (residues 80–99 and
105–124) that bindmixed ubiquitin-SUMO chains with high affin-
ity (Guzzo et al., 2012; Hu et al., 2012). These domains recruit488 Molecular Cell 75, 483–497, August 8, 2019BRCA1-A to sites of DNA damage (Guzzo
et al., 2012; Hu et al., 2012) and are con-
nected to BRCA1-A via a flexible linker
(Figure S4J).
We thus tested whether the RAP80 SIM/
UIM units serve in recruitment only or
whether they also contribute to preferential
cleavage of mixed SUMO ubiquitin chains.
For this, wemonitored degradation of (Ub)2
and SUMO/di-ubiquitin (SUMO-K63-diUb)
chains by BRCA1-A in gel-based cleavage
assays (Figure S5A).We found a small pref-
erence in cleavage of SUMO-K63-Ub2
chains in the presence of full-length
RAP80, but not with BRCA1-A variants
that lack theRAP80SIM-UIM2 (FigureS5B).
In light of the preferential cleavages of (Ub)4
over (Ub)2 chains, we then switched to
longer SUMO-K63 chainswith, on average,
more than 6 ubiquitin units. In the context
of these longer chains, the RAP80 SIM/
UIM module did not confer a robust effect
on cleavage (Figure S5C). This result sug-gests that the role of the RAP80 SIM/UIM module lies predomi-
nantly in recruiting the complex to sites of SUMO and ubiquitin
modifications.
BRCA1 Sequestration by BRCA1-A Complex
A key BRCA1-A function is to regulate BRCA1 activity in DSB
repair. BRCA1-A and BRCA1 form a complex that sequesters
BRCA1 distant from the site of damage, an important regulatory
step in HR (Goldstein and Kastan, 2015; Kakarougkas et al.,
2013). This is dependent on the presence of RAP80, and a
correctly assembled BRCA1-A complex, but does not require
BRCC36DUBactivity (Ng et al., 2016). The ABRAXASC terminus
phosphorylated at Ser406 binds the BRCA1-BRCT 1 (residues
1,642–1,736) and BRCT 2 (residues 1,756–1,855) domains
(BRCA1-BRCT) with an apparent Kd of1.2 mM, an affinity com-
parable to that of other BRCA1-BRCT interaction partners
(Badgujar et al., 2013; Wu et al., 2016). Given comparable affin-
ities with other BRCA1-BRCT binders, it was unclear how
Figure 4. BRCA1-A Forms a Defined High-Affinity Complex
with BRCA1
(A) In an MST assay measuring binding of labeled BRCA1-BRCT to full-length
BRCA1-A complex including phosphorylated p-Ser404/406 ABRAXAS C ter-
minus, BRCA1-BRCT is bound with nanomolar affinity. The assay measures
change of relative fluorescence during heating; values are Fnorm = Fhot / Fcold.
Error bars represent mean ± SD of n = 4 replicates. Back titration with
unlabeled BRCA1-BRCT confirms nanomolar affinity. Error bars represent
mean ± SD of n = 4 replicates.
(B) Crosslinking network of the BRCA1-A-BRCA1 complex. Proteins are
shown schematically as bars. Crosslinks are shown as black lines. The
crosslink between K360 of BRE and K1750 of BRCA1 is conditional on the
presence of p-Ser404/406 phosphorylation on ABRAXAS C terminus.
(C) Model of the BRCA1-A-BRCA1 high-affinity complex. One protomer of
ABRAXAS, BRE, and RAP80 is shown as cartoon, while the remainder of the
BRCA1-A complex is shown as gray surface. A BRCA1-BRCT dimer (blue,
cartoon) is depicted in a position that localizes K1750 of BRCA1 proximal to
K360 of BRE. The unstructured C-terminal regions of ABRAXAS are depicted
schematically as orange and gray lines. A di-ubiquitin (green, surface) is shown
modeled into the active site.BRCA1-A, an inhibitor of resection, can potentially sequester
BRCA1 away from other binding partners such as BACH1 or
CtIP that typically activate HR (Badgujar et al., 2013; Clapperton
et al., 2004; Shiozaki et al., 2004; Varma et al., 2005; Wu
et al., 2016).
We set out to quantify BRCA1 binding to BRCA1-A in the
context of the fully assembled complex. Activation of the DSBrepair checkpoint has been suggested to proceed via the dou-
ble-phosphorylated ABRAXAS variant p-Ser404/406 in conjunc-
tion with induced dimerization of the BRCA1-BRCT (Wu et al.,
2016). We generated the entire BRCA1-A complex with site-spe-
cifically phosphorylated ABRAXAS by ligating phosphorylated
C-terminal peptides by sortase-mediated transpeptidation (Fig-
ures S5D and S5E). In microscale thermophoresis (MST) exper-
iments, measuring binding of labeled BRCA1-BRCT domains to
the entire BRCA1-A complex bearing ABRAXAS p-Ser404/406,
we observed substantially higher affinity (Kd 80 ± 7 nM)
(Figure 4A) than what is typically reported for BRCA1-BRCT
domain binding. The doubly phosphorylated ABRAXAS
p-Ser404/406 integrated in the BRCA1-A complex thus provides
a high-affinity docking cradle for BRCA1, exceeding the affinity
of other known BRCA1 interactors by more than 10-fold (Badg-
ujar et al., 2013; Liu and Ladias, 2013; Ray et al., 2006; Shiozaki
et al., 2004; Varma et al., 2005).
The increased interaction between BRCA1 and the BRCA1-A
complex likely arises from increased avidity due to the dimeric
structure of the BRCA1-A arc but also potentially suggests
further contacts extending beyond the BRCA1-BRCT ABRAXAS
phosphopeptide interface. We compared the interaction be-
tween BRCA1-BRCT and non-modified or p-Ser404/406 phos-
phorylated BRCA1-A in a crosslinkingmass spectrometry exper-
iment and observed a specific crosslink between BRCA1-A
subunit BRE (Lys360) and BRCT (Lys1750) that was dependent
on the presence of p-Ser404/406 modifications in ABRAXAS
(Figure 4B). The unstructured linker in ABRAXAS that separates
the RAP80-binding domain from the phosphorylated BRCA1-
binding motif allows the BRCA1-BRCT dimer to reach BRE
(UEV-C) at either side of the arc (Figure 4C).
We have not observed higher-order assemblies of multiple
BRCA1-A arcs stabilized by BRCA1-BRCT in negative-stain
EM (data not shown) or mobility shift assays (Figure S5E) that
had previously been proposed (Kyrieleis et al., 2016). We also
did not detect a difference in activity when assaying the phos-
phorylated BRCA1-A complex in the presence or absence of
the BRCA1-BRCT (Figure S5F).
Our data instead support a model where ABRAXAS integrates
RAP80 specifically into BRCA1-A, thereby preferentially target-
ing the BRCC36 DUB to DNA repair foci with both SUMO and
K63-Ub chains. Following checkpoint activation, the phosphory-
lated ABRAXAS subunit in BRCA1-A provides the high-affinity
binding site for BRCA1 sequestration and inhibition away from
the break site.
BRISC-SHMT2a Architecture
BRISC and BRCA1-A are functionalized by the ABRO1 and
ABRAXAS subunits, respectively, that work together with dedi-
cated adaptor proteins. The BRISC core (BRCC36-ABRO1
MPN dimer, UEV-N and RWD domain of BRE) has the same
2-fold symmetrical arc shape and is structurally similar to
BRCA1-A (RMSD 2.8 A˚). The conformation of BRE UEV-C and
MERIT40, however, differs markedly, with MERIT40 in BRISC
rotated by 56 in respect to its position in the BRCA1-A crystal
structure. We found the structural change to be induced by
RAP80 binding to BRCA1-A (Figures 1A, 1C, 3A, and 3C).
Whereas RAP80 is constitutively integrated into BRCA1-A,Molecular Cell 75, 483–497, August 8, 2019 489
Figure 5. Metabolic Enzyme SHMT2a Binds Specifically to BRISC, Inactivating It
(A) The cryo-EM structure of BRISC-SHMT2a reveals why SHMT2a binds BRISC, but not BRCA1-A. While the ABRO1 isoleucine (Ile133) proximal to SHMT2a is
conserved in ABRAXAS, it points away from SHMT2a due to insertion of a proline (Pro137) into ABRAXAS.
(B) SHMT2 clashes with the position of the proximal ubiquitin of a ubiquitin dimer bound to the active site. Modeling di-ubiquitin (red, surface) into the BRCC36
active site reveals a substantial clash with the position of SHMT2a (green) in the BRISC-SHMT2a map (semitransparent surface).
(C) SHMT2a is a potent inhibitor of BRISC (2 nM), but not of BRCA1-A (5 nM), as shown by SHMT2a-mediated inactivation of BRISC in a DUB-activity assay using
IQF K63-linked di-Ubiquitin. A BRISC-RAP80 fusion construct (2 nM) containing the MPN domain of ABRO1 combined with the C terminus of ABRAXAS in-
tegrates RAP80 like BRCA1-A but is inhibited by SHMT2a like BRISC. Error bars represent mean ± SD of n = 3 replicates.SHMT2 has an established BRISC-independent role in one-car-
bon metabolism (Giardina et al., 2015; Kim et al., 2015). SHMT2
is expressed in a mitochondrial and a cytosolic form (SHMT2a)
(Anderson and Stover, 2009). SHMT2a is the form encountered
by BRISC in vivo, because BRISC does not enter mitochondria.
BRISC in isolation is present in a two-arc assembly (Figures 3A
and 3B; Figures S4F, S4G, and S4I) not suitable for high-resolu-
tion structure determination due to structural heterogeneity.
SHMT2a binding converts BRISC into a single-arc arrangement
(Figure 1C). The BRISC-SHMT2 complex is recruited to the K63-
modified IFNAR1 receptor and has been implicated in IFNAR1
deubiquitination (Zheng et al., 2013). Furthermore, BRISC-
SHMT2 controls viral Tat protein degradation in HIV-1-infected
cells (Xu et al., 2018). The BRISC-SHMT2a structure now illus-
trates how ABRO1 allows SHMT2a binding to BRISC and how
SHMT2a functionalizes the complex beyond what is expected
from an adaptor.
The BRISC-bound SHMT2a is catalytically inactive (Zheng
et al., 2013), which is explained by our structure. Active SHMT2a
when bound to its pyridoxal-50-phosphate (PLP) cofactor is a
tetramer (Giardina et al., 2015). In the absence of its cofactor,
mammalian SHMT2 forms a structurally ‘‘open’’ apo-SHMT2
dimer that is enzymatically inactive (Giardina et al., 2015).
SHMT2a bound to the center of the BRISC arc is present as a490 Molecular Cell 75, 483–497, August 8, 2019dimer, and each protomer forms an extended 1,161 A˚2 interface
involving subunits ABRO1, BRCC36, and BRE in BRISC (Fig-
ure 1C; Figure S5G). In complex with BRISC, the SHMT2a dimer
adopts the open conformation, the structural hallmarks of the
inactive PLP cofactor-free enzyme (Figures S5H and S5I).
Two key hydrophobic SHMT2a residues, Leu190 and Leu194,
pack against ABRO1 residues Ile133, Ser134, and Thr135 (Fig-
ure 5A). An extended loop in SHMT2a (residues Gly274-
Tyr288) contacts BRE residues Lys162-Ala167, and Phe195 of
SHMT2a interacts with Trp130 of BRCC36 (Figures S5J and
S5K). Mutation of the ABRO1-interacting SHMT2a residues
Leu190 and Leu194 to lysine reduced BRISC binding in bio-layer
interferometry by more than 10-fold (SHMT2a binding to BRISC:
apo Kd 46 nM, PLP-preincubated Kd 39 nM; SHMT2a
Leu190Lys, Leu194Lys: Kd 530 nM) (Figure S6A). Analogous
to what we saw for RAP80/ABRAXAS in BRAC1-A, it is the
BRISC-specific ABRO1 subunit, with help of the remainder of
the complex, that is required for SHMT2a integration.
SHMT2a Functions as a BRISC Inhibitor
A model of K63-linked di-ubiquitin chains on BRCC36 using
AMSH-LP as a template (Sato et al., 2008) finds SHMT2a poten-
tially blocking substrate access to the active site (Figure 5B). We
therefore tested whether BRISC is inhibited when in complex
Figure 6. BRISC and SHMT2 Share the Same Cellular Compartments In Vivo and Vary in Concentration across Cell Lines and Tissues
(A) Endogenous SHMT2 and ABRO1 colocalize to nucleus and cytosol in quantitative immunofluorescence experiments. Error bars represent mean ± SD.
SHMT2: n = 13 replicates. ABRO1: n = 9 replicates. Every image contained 2–10 individual cells.
(B) BRISC DUB activity at substrate and SHMT2 concentrations encountered inside healthy and diseased human cells ranges from fully active to completely
inhibited. BRISC DUB activity corresponding to the concentrations of SHMT2a and ABRO1 in HeLa cells is shown in red.
(C) Concentrations of ABRO1 and endogenous SHMT2 in healthy human tissues (gray squares) and cancer cell lines (black circles) suggest that BRISC is
attenuated by no more than 50% in healthy human cells but mostly inhibited in cancer cell lines. Concentrations of SHMT2 and ABRO1 corresponding to HeLa
cells are shown in red.with SHMT2a. For this, we monitored the cleavage of K63-linked
(Ub)2 substrates by BRISC in the presence of SHMT2a. In fluo-
rescent di-ubiquitin cleavage assays, SHMT2a inhibited K63-
linked (Ub)2 cleavage by BRISC in a concentration-dependent
manner, with an estimated apparent Ki 7 ± 0.3 nM, which is
comparable to the binding constant between SHMT2a and
BRISC determined by bio-layer interferometry (Kd 39 nM) (Fig-
ures S6A and S6B). Mutating SHMT2a residues Leu190 and
Leu194 required for ABRO1 binding to Lys190 and Lys194 abol-
ished BRISC inhibition by SHMT2a (Figure S6C). In addition to a
possible role of SHMT2a in targeting BRISC to membranes,
SHMT2a serves as a soluble DUB inhibitor when engaged. We
find that the inhibitory effect of SHMT2a on BRISC is not affected
by concentrations of PLP, serine, glycine, or tetrahydrofolate
tested (Figures S6D–S6G).
We then tested whether SHMT2a inhibition was specific to
BRISC and examined which epitopes of ABRO1 are involved.
Unlike BRISC, BRCA1-A was not inhibited by SHMT2a, but a
chimeric BRCA1-A complex bearing the MPN domain of
ABRO1 (1-260) instead of ABRAXAS (1-269) was inhibited by
SHMT2a (Figure 5C). Although in BRISC the SHMT2a-binding
interface consists of BRE, ABRO1, and BRCC36, it is primarily
the BRISC-specific subunit ABRO1, this time through its MPN
domain, that confers specific SHMT2a binding. While ABRAXAS
contains the equivalent of the SHMT2a-binding ABRO1 Ile133
residue (Ile139), an adjacent deletion of one residue flips the
isoleucine side chain away from the interface, providing the
structural basis of specificity (Figure 5A). SHMT2a thus functions
as a specific, high-affinity protein inhibitor of the BRISC MPN
DUB complex by restricting access to the active site, and this
property is specifically conferred by ABRO1. Since BRCA1-A
does not bind SHMT2a, BRCA1-A activity in DNA repair
signaling is unaffected by nuclear SHMT2a.
SHMT2a as a Cell-Type-Dependent Regulator of BRISC
Activity
The observed high-affinity binding and potent mutual inhibition
between BRISC and SHMT2a in vitro led us to examine whetherthe concentration of BRISC-SHMT2a and its subcellular distri-
bution would permit regulation in vivo. Pre-processed SHMT2
and a mature form cleaved after residue Ser29 predominantly
localized to the mitochondria in mouse liver cells (Anderson
and Stover, 2009). SHMT2a, however, is found in comparable
amounts in the nucleus, cytosol, and mitochondria (Anderson
and Stover, 2009). All SHMT2 isoforms are expected to
inhibit BRISC based on our structure. To determine BRISC
and total SHMT2 subcellular localization, we carried out
immunofluorescence experiments using a SHMT2 antibody for
an epitope common to all three forms of SHMT2 (Figure S6H).
We found endogenous SHMT2 in HEK293 cells present in the
cytosol (62.1% ± 11.7%), nucleus (30.3% ± 10.0%), and mito-
chondria (7.6% ± 2.2%). The BRISC-specific subunit ABRO1
was found in the cytosol (66.2% ± 8.8%) and in the nucleus
(32.6%±8.2%) butwas not detected inmitochondria (Figure 6A).
Using quantitative mass spectrometry, concentrations on the or-
der of1 mMSHMT2 and20–100 nMBRISCweremeasured in
HeLa cells (Hein et al., 2015). To determine the expected extent
of BRISC inhibition by SHMT2, we carried out in vitro internally
quenched fluorescent (IQF) di-ubiquitin cleavage assays. At con-
centrations of BRISC and SHMT2a found in HeLa cells, BRISC
DUB activity is expected to be inhibited by SHMT2 up to 50%
(Figure 6B). In cancer cell lines surveyed by quantitative mass
spectrometry, endogenous SHMT2 is present in concentrations
exceeding 1 mM (Hein et al., 2015; Wilhelm et al., 2014), which
corresponds to BRISC inhibition of more than 80% in our assays
(Figure 6C). Across a variety of cell lines and tissues, SHMT2 and
BRISC therefore are present at concentrations that permit
BRISC inhibition, allowing SHMT2 to potentially regulate
BRISC-mediated K63 deubiquitination activity.
DISCUSSION
Our results demonstrate how a near identical deubiquitinase
core is functionalized for radically different cellular purposes
through the ABRO1 and ABRAXAS subunits and how these sub-
units confer differential BRCC36 targeting and regulation.Molecular Cell 75, 483–497, August 8, 2019 491
Figure 7. Assembly and Regulation of
BRCA1-A and BRISC
Schematic summary of BRCA1-A and BRISC
function.The BRCA1-A complex is an important safeguard for genome
stability, which is frequently mutated in inherited breast cancers.
BRCA1-A serves three roles in DSB repair: (1) recruitment to foci
by stable RAP80 integration (Kim et al., 2007; Sobhian et al.,
2007; van Wijk et al., 2012; Wang et al., 2007), (2) delimiting
the K63-Ub boundary around breaks (Ng et al., 2016), and (3) in-
hibiting resection by sequestering BRCA1 and limiting its avail-492 Molecular Cell 75, 483–497, August 8, 2019ability for the BRCA1/2-PALB2-RAD51
complex (Goldstein and Kastan, 2015;
Typas et al., 2015).
Our work demonstrates that
ABRAXAS functionalizes BRCA1-A for
all three tasks. We show that RAP80 is
an integral, structural part of the
BRCA1-A complex as it interacts not
only with ABRAXAS, but has substantial
interaction surfaces with two additional
subunits, MERIT40 and BRE. Loss of
MERIT40, or BRE, compromises
BRCA1-A integrity and genome safe-
guarding, which is explained by the
structure. Loss of the RAP80 SIM-
UIM2 domains gives rise to substantial
deficiencies in BRCA1-A targeting to
breaks and concomitant repair defects
(Guzzo et al., 2012). The BRCA1-A ar-
chitecture with the RAP80 SIM-UIM2
domains bestows preferential recruit-
ment to mixed SUMO/K63-Ub2 chains.
ABRAXAS recruits RAP80, and thereby
localizes BRCA1-A to mixed chains,
and likely interlinks K63-ubiquitin and
SUMO signaling at repair sites and de-
limits the K63-ubiquitin boundary
around breaks.
BRCA1-A plays an important role
engaging and stabilizing BRCA1 at 2–10
kb distance from the breaks and inacti-
vating it (Goldstein and Kastan, 2015;
Typas et al., 2015). Binding of the
BRCA1-BRCT domains to the ABRAXAS
phospho-peptide is mutually incompat-
ible with binding phosphorylated CtIP or
BACH1 (CtIP: Kd3.7 mM; BACH1:
Kd0.9 mM) (Shiozaki et al., 2004; Varma
et al., 2005; Wu et al., 2016). The BRCA1-
A arc architecture, with phosphorylation
sites on ABRAXAS close to its C
terminus, sequesters BRCA1 in a Kd
60–80 nM complex, which is signifi-
cantly tighter than the affinities reportedfor other BRCA1-BRCT interactions. Cradled distal from break
sites within the high-affinity BRCA1-A scaffold contacting BRE
and ABRAXAS, BRCA1 is unable to engage other activators of
resection providing a structural rationale for the observed
BRCA1 inhibition.
The BRCA1-A architecture provides the circuitry for BRCA1
sequestration and directed deubiquitination through distinct
structured modules. A mutation in BRCA1-BRCT (e.g., Lys1702-
Met), which impairs ABRAXAS binding, gives rise to a hyper-
resection phenotype equivalent to the loss of RAP80/BRCA1-A
(Dever et al., 2011), demonstrating that both modules are essen-
tial for BRCA1-A function. BRCA1 sequestration and targeting to
SUMO-ubiquitin marks critically depend on ABRAXAS yet at the
same time involve other core subunits present in both BRISC and
BRCA1-A.
The BRISC complex largely operates outside the nucleus,
regulating K63-ubiquitin levels in immune signaling. Whether
BRISC activity can be regulated was unclear previously. We
find that in BRISC, it is also the subcomplex-specific subunit
ABRO1 that functionalizes the complex, enabling SHMT2a bind-
ing. Cellular proteases are typically produced as inactive proen-
zymes (Khan and James, 1998), complexed to soluble proteina-
ceous inhibitors (Farady and Craik, 2010), or embedded in
macromolecular complexes that are autoinhibited in the
absence of a substrate (Lingaraju et al., 2014; Pathare et al.,
2014; Worden et al., 2014; 2017). Overall, the MPN DUB family
is a notable exception, with no soluble protein inhibitors
described so far (Leznicki and Kulathu, 2017; Sahtoe et al.,
2015; Vander Linden et al., 2015). While assembled BRISC and
BRCA1-A complexes assume an active, non-autoinhibited,
default state, BRISC binding to the soluble metabolic enzyme
SHMT2a results in mutual inhibition of both SHMT2a and BRISC
activity.
Endogenous co-purification (Sowa et al., 2009; Zheng et al.,
2013) and subcellular co-localization of BRISC and SHMT2
establish that a reciprocally inhibited BRISC-SHMT2a complex
forms in target cells. The interaction between SHMT2a and
BRISC, and the ensuing inhibition, could be regulated, for
example, through posttranslational modifications at the inter-
face. HowSHMT2a inhibition of BRISC can facilitate the reported
BRISC-dependent deubiquitination of IFNAR1 presently remains
unclear (Zhenget al., 2013).Combining the results of in vitroenzy-
matic studies and the reported variations in SHMT2a andABRO1
levels across different human cell lines and tissues, we expect
that the relative BRISC activity is impacted by SHMT2 levels in
some tissues (e.g., in lymph nodes, colon, and liver) and is largely
unaffected in others (e.g., in brain and reproductive organs) (Uh-
le´n et al., 2015, 2017;Wilhelmet al., 2014).Wepredict inhibition to
apply predominantly to the BRISC/DUB and not to themetabolic
enzyme SHMT2, because SHMT2 is present in large (>10-fold)
excess over BRISC in many tissues (Figure S6I). We note
that cancer cells frequently increase reliance on one-carbon
metabolism by overexpression of SHMT2 by >10-fold to adapt
to the hypoxic conditions inside tumors (Amelio et al., 2014;
Kim et al., 2015; Wilhelm et al., 2014) (Figure S7). Future work is
needed to assess how SHMT2 expression affects K63-Ub ho-
meostasis across different tissues in health and disease.
More than 20,000 ubiquitination sites in mammalian cells are
deubiquitinated by a pool of 100 DUBs (Leznicki and Kulathu,
2017; Mevissen and Komander, 2017). We find the BRCC36-
containing BRCA1-A and BRISC complexes to be modular
DUBs, with ABRAXAS and ABRO1 specifically integrating
accessory factors RAP80, BRCA1, or SHMT2, respectively,
and conferring targeting and regulation (Figure 7). Specific bind-
ing of these accessory factors is driven through interactions bythe subcomplex-specific ABRO1/ABRAXAS subunits, com-
bined with contacts by subunits shared between BRISC and
BRCA1-A. Interestingly, it is the ABRO1 and ABRAXAS subunits
that drive SHMT2 and RAP80/BRCA1 integration, respectively,
but their integration involves additional contributions from the
common core subunits. The BRISC/BRCA1-A structures and
their functional dissection presented here reveal modularity in
the MPN DUB family reminiscent to what has been described
for ubiquitin ligases of the cullin-RING family (Petroski and De-
shaies, 2005). We expect similar targeting and regulatory princi-
ples to apply to most multimeric DUB assemblies.STAR+METHODS
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Cell culture of human osteosarcoma (U2OS) cells
U2OS cells (female, a gift from Dr. Durocher) were cultured at 37C in an atmosphere of 5% CO2 in DMEM supplemented with an-
tibiotics, 10% fetal calf serum and glutaMAX (GIBCO). They were not otherwise authenticated.
METHOD DETAILS
Protein expression and purification of BRCA1-A and BRISC
Expression constructs for the BRCA1-A and BRISC complex were synthesized (Genescript and Geneart, for Mus musculus and
Homo sapiens, respectively) and cloned into pFastBac (ThermoFisher) vectors for insect cell expression using standard molecular
biology techniques. Native codon usagewas preservedwith the exception of the removal of NotI and KpnI restriction sites. Truncated
constructs were cloned from full-length constructs using standard molecular biology techniques. All constructs were verified by
sequencing (Microsynth). Baculoviruses were generated in Spodoptera frugiperda Sf9 cells (ThermoFisher) using the Bac-to-Bac
system (ThermoFisher). For recombinant protein expression of the BRCA1-A and BRISC complex or subcomplexes, Trichoplusia
ni High Five cells (ExpressionSystems) were coinfected with baculoviruses encoding the desired proteins. BRCA1-A complex was
expressed by co-infection of High Five cells with viruses encoding (full-length, engineered or truncated) ABRAXAS, BRCC36,
BRE, MERIT40, and RAP80. BRISC complex was expressed by co-infection of High Five cells with viruses encoding (full-length, en-
gineered or truncated) ABRO1, BRCC36, BRE, and MERIT40. The BRE-MERIT40 complex was expressed by co-infection of High
Five cells with viruses encoding BRE and MERIT40. Cells were harvested by centrifugation 36 h after infection, resuspended in lysis
buffer (50 mMHEPES pH 7.4, 200mMNaCl, 0.1% (v/v) Triton X-100, 1 mMPMSF, 0.2 mM TCEP) supplemented with 13 SigmaFast
protease inhibitor cocktail (Sigma-Aldrich) and disrupted by sonication. Cell debris was removed by ultracentrifugation (45 min at
40,000g) and the supernatant was filtrated through Miracloth (EMD Millipore) and subsequently applied to Strep-Tactin resin (IBA
Lifesciences). The affinity resin was washed (wash buffer: 50 mM HEPES pH 7.4, 200 mM NaCl, 0.2 mM TCEP) and bound protein
was subsequently eluted (elution buffer: 50 mM HEPES pH 7.4, 200 mM NaCl, 0.2 mM TCEP, 2.5 mM D-desthiobiotin). The eluted
complex was subjected to anion exchange purification on a Poros 50 HQ (ThermoFisher) column using a linear gradient (50 mM Tris-
HCl pH 8.0, 0.2-1 M NaCl, 0.2 mM TCEP). Fractions containing protein were concentrated by ultrafiltration (Amicon Ultra-15, 30 kDa
molecular weight cutoff). For crystallization, concentrated BRCA1-A was incubated at room temperature (RT) with 1% (w/w) tobacco
etch virus (TEV) protease for 1 h to remove affinity tags. Samples were finally subjected to gel filtration on a Superose 6 column (Ther-
moFisher), where buffer was exchanged to crystallization buffer (20 mM HEPES pH 7.4, 150 mM NaCl, 0.2 mM TCEP) or storage
buffer (50 mM HEPES pH 7.4, 200 mM NaCl, 0.2 mM TCEP).
BRCA1-A crystallization
BRCA1-A (10 mg/ml in crystallization buffer) was crystallized in Cryschem plates (Hampton Research) by vapor diffusion equilibra-
tion against 500 ml well solution. Crystallization trials were set up by mixing 1 ml BRCA1-A solution with 1 ml well solution (100 mMe3 Molecular Cell 75, 483–497.e1–e9, August 8, 2019
MES-KOH pH 5.6, 200 mM MgCl2, 8% (w/v) PEG6000) at room temperature. The plate was subsequently incubated at 4
C and
rhombohedral plate-like crystals grew. They obtained their largest dimension after three days. Crystals were cryoprotected by
gradual supplementation of the crystal growth drop with ethylene glycol to a final concentration of 25% (v/v), and flash-cooled
in liquid nitrogen for X-ray diffraction analysis.
BRCA1-A crystal structure determination
BRCA1-A formed crystals belonging to the orthorhombic space group P212121 with unit cell parameters a = 97.1 A˚, b = 112.6 A˚,
c = 431.3 A˚, and contained a single copy of the complex, with a molecular weight of 333 kDa in the asymmetric unit and solvent con-
tent of 65%. These crystals typically diffracted X-rays anisotropically to 4.2 A˚ resolution. All diffraction data were collected at the
Swiss Light Source (SLS) from crystals cooled to 100 K as described. In a native zinc single wavelength anomalous dispersion (SAD)
phasing approach, high-multiplicity diffraction data were collected from a fixed position on a single crystal with a low-dose X-ray
beam at the zinc K-edge absorption peak wavelength (1.2816 A˚; fʹ = 9.23, f00 = 4.97) from SLS beamline X10SA with a Pilatus
6M detector (Dectris). Data were processed with XDS (Kabsch, 2010). Two sites corresponding to the BRCC36 active site Zn2+
ions were found using the anomalous intensities in the resolution range 118-7.5 A˚ with SHELXD (Sheldrick, 2008). SAD phases
were calculated from the two sites after refinement in PHASER (McCoy et al., 2007) to 7.3 A˚ resolution, giving an overall figure-of-
merit of 0.29. Density modification was carried out initially with PIRATE (Cowtan, 2000) from the CCP4 suite (Winn et al., 2011) at
7.3 A˚ resolution and thereafter with PARROT (Cowtan, 2010) or phenix.resolve (Adams et al., 2010). SAD phasing was reinitiated
in PHASER using the density modified map as the partial structure (MR-SAD) and followed by a round of density modification to
generate an improved electron density map. By iterating this procedure, the phases were progressively extended to 6 A˚ resolution,
yielding substantially improved electron density. The atomic model was built interactively in COOT (Emsley et al., 2010). At first
domain fragments were placed in the electron density from known structures for the ABRAXAS-BRCC36 MPN domain
dimer (PDB: 4d10; Lingaraju et al., 2014), the BRE UEV-C domain (PDB: 4YII; Brown et al., 2015), and MERIT40 (PDB: 2X5N; Rie-
dinger et al., 2010), and ideal ⍺-helices in other regions clearly defined by tubes of electron density. Dramatic improvement to the
interpretability of the electron density was achieved through many cycles of poly-serine model building followed by consecutive
refinement in CNS (Schro¨der et al., 2010) with non-crystallographic symmetry (NCS) and deformable elastic network restraints
(ɣ = 0 andwDEN = 100), andREFMAC (Nicholls et al., 2012) with jelly-body restraints (s = 0.01 for 100–500 cycles), followed by density
modification with NCS averaging. Refinement was carried out using SAD phase restraints against the Zn-SAD data in resolution
range 118-4.3 A˚, or data to comparable resolution obtained from different crystals. Once the quality of the electron density indicated
that completing the atomic model would be feasible, focus was shifted to assigning its amino acid sequence, and increasing consid-
eration was given to the validation characteristics of the refined coordinates. Diffraction data for model completion and refinement
were assembled by multi-crystal merging across seven crystals, improving overall data quality and the measurability of reflections in
a cone around the a* (a) axis, whichwas theweakest direction of anisotropy. Diffraction datawere obtained SLS beamline X06SAwith
an Eiger X 16M detector (Dectris) at a wavelength of 1 A˚ and processed using DIALS (Winter et al., 2018), with diffraction geometry
parameters adjusted by joint refinement across multiple sweeps obtained from several crystals. Intensity data were combined
with POINTLESS (Evans, 2011) and scaled and merged with AIMLESS (Evans and Murshudov, 2013). Structure factor amplitudes
treated for anisotropy were calculated from the final intensities by STARANISO (Global Phasing Ltd.), applying a high-resolution cut-
off of 1 I/sI. Amino acid sequence assignment was guided by the positions of methionine and cysteine residues determined by MR-
SAD for the native sulfur atoms in combinationwith themercury atoms found for a crystal soaked in p-chloromercuribenzoic acid. The
model was rebuilt and extended with COOT in cycle with refinement against data extending to 3.75 A˚ resolution variously with auto-
BUSTER (Global Phasing Ltd.), phenix.refine, ROSETTA (Wang et al., 2016), and REFMAC. Development of the refinement strategy
was guided by analysis with PDB-REDO (Joosten et al., 2014). Final refinement was performed with ISOLDE followed by REFMAC
(Croll, 2018; Nicholls et al., 2012). Analysis of the final model with MOLPROBITY (Chen et al., 2010) indicates that 92.5% of the
residues are in favorable regions of the Ramachandran plot, with 1.2% outliers. Detailed crystallographic data processing and refine-
ment statistics are in Table 1.
Protein expression and purification of SHMT2a
The expression construct for SHMT2 encoding the cytosolic form SHMT2a was obtained from the SGC structural genomics con-
sortium and contains a mutation A264T, which is distal from the BRISC interaction surface. In comparison with the PLP-bound
SHMT2 structure (PDB: 4PVF) there is no indication that the mutation affects the overall structure (PDB: 6DK3). SHMT2a was ex-
pressed at 15C overnight in Escherichia coli BL21 (DE3) pRIL (Agilent Technologies) in auto-induction medium (Studier, 2005). Cells
were resuspended in lysis buffer (50mMHEPESpH 7.4, 200mMNaCl, 0.1% (v/v) Triton X-100, 1mMPMSF, 13SigmaFast protease
inhibitor (Sigma-Aldrich), 0.2 mM TCEP) and lysed by sonication. Cell debris was subsequently removed by ultracentrifugation. The
supernatant was subjected to Ni-NTA (Sigma-Aldrich) affinity chromatography. The protein was eluated using steps of 5, 20, 50, 100,
500 mM imidazole (buffer: 100 mM HEPES pH 7.4, 200 mM NaCl, 0.2 mM TCEP) and pooled protein fractions were concentrated by
ultrafiltration (Amicon Ultra-15, 30 kDa molecular weight cutoff, Merck) and separated by gel filtration on a Superdex 200 column
(ThermoFisher). SHMT2a was purified in its apo-form lacking pyridoxal 5ʹ-phosphate (PLP). To assemble SHMT2 tetramers with
bound cofactor, PLP (Sigma-Aldrich) was added to SHMT2a prior to gel filtration. The protein fractions obtained showed the char-
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Cryo-electron microscopy
For structure determination of BRISC-SHMT2 complex by cryo-electron microscopy equal volumes of human BRISC (12mg/ml) and
SHMT2 (9.3mg/ml) weremixed and incubated at room temperature for 15min. The complexwas purified by gel filtration (Superose 6,
GE Healthcare) and the peak fraction (0.44 mg/ml) was collected. Tween-20 was added to a final concentration of 0.001% (v/v). Gold
foil grids UltrAuFoil 1.2/1.3 300 mesh (Quantifoil) were glow discharged in a Solarus plasma cleaner (Gatan) for 12 s in a H2/O2 envi-
ronment prior to vitrification. A 4 ml sample was applied to the grid and a protocol consisting of 30 s pre-blot incubation, 2 s blotting
and no post-blot incubationwas utilized for vitrification using a Leica EMGPplunge freezer (LeicaMicrosystems) operated at 4Cand
80% humidity. Data were collected automatically with EPU (ThermoFisher) on a Cs corrected (CEOS) FEI Titan Krios (ThermoFisher)
electron microscope at 300 kV. Zero-energy loss micrographs were recorded using a Gatan K2 summit direct electron detector (Ga-
tan) in counting mode located after a Quantum-LS energy filter operated with a slit width of 20 eV. The acquisition was performed at a
calibrated magnification of 58140x in EFTEM mode yielding a pixel size of 0.86 A˚ and a dose rate of 4.7 e/(px$s). Exposures of 7 s
were fractionated into 40 frames leading to a total dose of 45 e/A˚2. The defocus values of the dataset ranged from 0.5 to 5 mm.
Image processing
Parallel to acquisition with EPU the micrograph stacks were corrected for drift, the CTF was determined, and particles were auto
picked using CryoFLARE (in house development; www.cryoflare.org) for automation of the process. The drift correction was per-
formed with the programmotioncor2 (Li et al., 2013). A sum of all 40 frames was generated with and without applying a dose weight-
ing scheme. The CTF was fitted using GCTF (Zhang, 2016) on the non-dose-weighted sums and the particles were picked using
Gautomatch (Dr. Kai Zhang, Cambridge) on the dose-weighted sums. A total of 1822 micrograph movies were acquired from which
332,598 particles were selected. The corrected and picked dataset was subsequently subjected to extraction with a box size of 350
px from the dose-weighted sums and resulting particles were 2D classified. Six rounds of 2D classification inRELION (Scheres, 2012)
and selection of good classes were performed to remove ice contamination, junk particles, and particles touching each other due to
micro-aggregation. The 2D classfication and selection process yielded a refined dataset of 44,381 particles. An initial 3D model was
generated in RELION without imposing symmetry. The initial model was rotated in chimera to align the twofold symmetry axis of the
complex with Z and afterward symmetrized in C2 using EMAN2 (Tang et al., 2007). The symmetrized map was used as a starting
model for a 3D classification into 3 classes in RELION. The largest class containing 35,595 particles was selected for 3D refinement.
The refined dataset was used to re-extract particles fromdose-weighted sumswhere the first 3 and the last 20 frameswere excluded.
The re-extracted dataset was subjected to another round of 3D refinement yielding a map at 3.9 A˚ resolution. The refinements fol-
lowed the gold-standard procedure and the resolution estimates are based on the Fourier shell correlation curve (FSC) at the 0.143
criterion (Rosenthal and Henderson, 2003) after post-processing. The final map was corrected for the modulation transfer function
(MTF) of the K2 detector and sharpened by applying a negativeB factor estimated automatically withinRELION. Variations in the local
resolution were estimated from the independent half-maps of the refinement using the programResMap (Kucukelbir et al., 2014). Our
BRCA1-A atomic model and SHMT2 (PDB: 5V7I, Ducker et al., 2017) were docked into the BRISC-SHMT2a cryo-EM map with
COOT. Using tools from ROSETTA suite and PROMALS3D (Pei et al., 2008), the human BRISC amino acid sequence was assigned
by threading, the protomer conformations were optimized, and refinement with iterative local rebuilding was carried out. The final
model was obtained after minimal cycles of rebuilding with COOT and refinement with phenix.real_space_refine. Detailed cryo-
EM data collection, refinement, and validation statistics are in Table 2.
Chain length specific degradation assay
To assess chain length dependence of human BRISC and BRCA1-A (truncated RAP80) DUB activity, 4 mg K63-linked (Ub)2, (Ub)3, or
(Ub)4 (Boston Biochem) were incubated with 5 nM DUB complex in 210 ml volume (gel filtration buffer). Samples (10 ml) were taken at
regular intervals, reactions were stopped by addition of SDS-PAGE loading buffer and subsequently samples were analyzed qual-
itatively by SDS-PAGE (AnyKD, Bio-Rad) and silver stain (Bio-Rad). Initial velocity of cleavage of (Ub)2 at variable BRCA1-A concen-
trations (0-500 nM) wasmeasured using 200 nM internally quenched K63-linked (Ub)2 as substrate in assay buffer (50mMHEPES pH
7.0, 100 mM NaCl, 0.5% (w/v) BSA, 0.03% (w/v) Brij-35, 0.2 mM TCEP). Relative TAMRA fluorescence was monitored in 10 s time
increments (excitation at 540 nm, emission at 590 nm) and assays were carried out at 22C in black flat-bottom high-base 386-well
plates (Greiner Bio-One) using a Pherastar plate reader (BMG Labtech). Initial velocity in relative fluorescence units per second was
determined by linear regression.
Nuclear magnetic resonance experiments
NMR experiments were conducted at 25C on a Varian INOVA 600-MHz spectrometer equipped with 1H, 13C, 15N triple-resonance,
z axis pulsed-field-gradient probe. All samples were prepared in a buffer 50mMHEPESpH 7.4, 200mMNaCl, 0.2mMTCEP, and 5%
D2O. All NMR data were processed with NMRPipe and NMRDraw (Delaglio et al., 1995). NMR data were obtained from standard 1D
single-resonance experiments acquired on 100 mM uniformly 15N–labeled Ubiquitin purchased from BostonBiochem. 15N-HSQC
titration of 50 mM 15N-Ubiquitin proteins was done by stepwise addition of MERIT40 truncated, MERIT40 full-length mixed 1:1
with BRE, or Merit40 truncated mixed 1:1 with BRE from high concentration stocks. 15N-HSQC titration data were analyzed with
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(Ub)4 pre-orientation assay
Human BRCA1-A (containing truncated RAP80) at a concentration of 10 nM was mixed with 1 mM (Ub)4 with a TAMRA label on the
proximal (Life Sensors) and distal (Boston Biochem) Ubiquitin, respectively, in assay buffer (50 mM HEPES pH 7.0, 100 mM NaCl,
0.5% (w/v) BSA, 0.03% (w/v) Brij-35, 0.2 mM TCEP). Samples (10 ml) were taken at regular intervals and reactions were stopped
by addition of SDS-PAGE loading buffer. Gels were analyzed by SDS-PAGE (AnyKD, Bio-Rad) and imaged with a Typhoon FLA
9500 imager (GE Healtchare Life Sciences).
Cell biology and fluorescence microscopy of DNA repair foci
U2OS parental and RAP80 knockout cells were used. The knockout of RAP80 was confirmed by western blot analysis using RAP80-
specific antibody. The GFP-RAP80(WT) plasmid was a gift of Dr. A.M. Jetten (Yan et al., 2002). This plasmid was used to remove the
AIR domain (residues 274-334) to generate GFP-RAP80(DAIR). Both parental and RAP80 knockout cells were seeded on 18mmcov-
erslips and transiently transfected with 25 ng GFP-NLS, 500 ng GFP-RAP80(WT) or 500 ng GFP-RAP80(DAIR) using lipofectamine
2000 according to the manufacturer’s instructions. At 24 h after transfection, cells were irradiated with 2 Gy using a YXlon X-ray
generator (YXlon International, 200 KV, 10 mA, dose rate 2 Gy/min) and after 1 h cells were fixed with 4% formaldehyde in PBS
for 15 min at room temperature. Cells were treated with 100 mM glycine in PBS for 10 min to block unreacted aldehyde groups. Cells
were rinsed with phosphate-buffered saline and equilibrated in WB (PBS containing 0.5% BSA, and 0.05% Tween 20; Sigma-Al-
drich). Antibody steps and washes were in WB. The primary antibodies (mouse BRCA1 Santa Cruz sc-6954; 1/100, and
rabbit MDC1 Abcam ab11171; 1/1000) were incubated overnight at 4C. Detection was done using goat anti-mouse or goat anti-rab-
bit Ig coupled to Alexa 555 or 647 (1/1000; Invitrogen Molecular probes). Samples were incubated with 0.1 mg/ml DAPI and mounted
in Polymount. Images of fixed samples were acquired on a Zeiss AxioImager M2 widefield fluorescence microscope equipped with
63x PLAN APO (1.4 NA) oil-immersion objectives (Zeiss) and an HXP 120 metal-halide lamp used for excitation. Fluorescent probes
were detected using the following filters: DAPI (excitation filter: 350/50 nm, dichroic mirror: 400 nm, emission filter: 460/50 nm), GFP
(excitation filter: 470/40 nm, dichroic mirror: 495 nm, emission filter: 525/50 nm), Alexa 555 (excitation filter: 545/25 nm, dichroic
mirror: 565 nm, emission filter: 605/70 nm), and Alexa 647 (excitation filter: 640/30 nm, dichroic mirror: 660 nm, emission filter:
690/50 nm). Images were recorded using ZEN 2012 software. The number, intensity, and size of BRCA1 foci was analyzed for all
conditions in ImageJ using a custom-built macro that enabled automatic and objective analysis of the foci as described previously
(Typas et al., 2015). Cell extracts were generated by boiling cell pellets in Laemmli buffer, separated by SDS-PAGE and transferred to
Immobilon-FL PVDFmembranes (Millipore). Membranes were probed with the following antibodies: rabbit anti-RAP80 (Bethyl A300-
764, 1/1000), mouse anti-GFP (Roche 11814460001, 1/2000), and mouse anti-tubulin (Sigma T6199, 1/5000). Protein detection was
done using the Odyssey infrared imaging scanning system (LI-COR Biosciences). Secondary antibodies were purchased from
Biotium.
Co-expression in insect cells and pull-down
High Five cells were grown to 5,106 cells/ml and 5 ml were mixed with 5 ml of fresh medium supplemented with penicillin and strep-
tomycin and infected by addition of 200 ml of P2 virus. Cells were harvested after 40 h, pelleted. and lysed by sonication in lysis buffer
(50 mMHEPES pH 7.4, 200mMNaCl, 0.1% Triton X-100, 0.2 mMTCEP). Lysate was cleared by centrifugation (13200 rpm at 30min,
4C). 25 ml Ni-NTA (Sigma-Aldrich) or 15 ml Strep-Macro-Prep (IBA AG) were added and sample was incubated on a shaking platform
at 4C for 30 min. After two washes with lysis buffer, the resin was resuspended in SDS-PAGE sample buffer and analyzed by
SDS-PAGE.
Analysis of RAP80 incorporation and double arc formation
A fusion gene ofmouse ABRO1 (residues 1-260) and ABRAXAS (residues 269-407) was synthesized by IDT and cloned into pFastBac
baculovirus expression vector. Fusion complex was prepared as described for BRCA1-A complex, using fusion virus instead of
ABRAXAS. Oligomerization was analyzed by SDS-PAGE (AnyKD gels, BioRad) and native PAGE electrophoresis (7.5% (w/v) acryl-
amide gels, BioRad) using 10 mg of complex for each lane. Gels were stained with Coomassie brilliant blue.
Negative stain electron microscopy
BRISCwas prepared for electron microscopy using the GraFix method (Kastner et al., 2008). BRISC complex (10mg/ml) was layered
on top of a 10%–30% (w/v) glycerol gradient (50 mM HEPES pH 7.4, 150 mM NaCl, 0.2 mM TCEP) with an increasing concentration
(0%–0.2% w/v) of glutaraldehyde (EMS) and subjected to ultracentrifugation (Beckman SW40Ti rotor, 32000 rpm, 19 h, 4C). The
fraction containing BRISC was directly applied to glow discharged Quantifoil grids (S7/2, Cu 400 mesh, Quantifoil Micro Tools
GmbH), blotted, and stained with 2% (w/v) uranyl acetate. Data were collected using a Tecnai T12 electron microscope (FEI) at
100 kV, with a pixel size of 3.08 A˚/pixel at the specimen level. Imageswere recordedwith a TVIPS TemCamF416with varying defocus
(0.5 to 1.5 mm) and processed with the EMAN2 image processing suite (Tang et al., 2007).
Di-ubiquitin preparation
K63-linked di-Ubiquitin (K63-(Ub)2) contains WT Ubiquitin linked by K63 to an N-terminally his-tagged Ubiquitin bearing a K63R mu-
tation. To prepare K63-diUb, 300 mMhis-tagged Ubiquitin K63R and 100 mMwild-type (WT) Ubiquitin were incubated with 0.1 mME1,Molecular Cell 75, 483–497.e1–e9, August 8, 2019 e6
2.5 mMUbc13, 2.5 mMUbe2V2 and 0.55 mMRNF4RING at 20Covernight in a buffer containing 3mMATP, 5mMMgCl2, 50mMTris
pH 7.5, 150 mM NaCl, 0.5 mM TCEP and 0.1% NP40. RNF4RING contains one full-length RNF4 linearly fused to a second
RING domain of RNF4 (Plechanovova´ et al., 2011). The reaction mixture was purified by Ni-NTA chromatography. The Ni-NTA elution
contained His-tagged (Ub)2 and His-tagged ubiquitin K63R, which were separated on a HiLoad Superdex 75 16/600 gel filtration col-
umn (ThermoFisher) in a buffer containing 50 mM Tris pH 7.5, 150 mM NaCl and 0.5 mM TCEP.
Preparation of SUMO/Ubiquitin mixed chains
SUMO-2-K63-(Ub)2 was prepared using SUMO-2-Ub as a substrate. SUMO-2-Ub containedWT ubiquitin linearly fused to a C-termi-
nally His-tagged SUMO-2 (Bett et al., 2015). A second Ubiquitin bearing a K63R mutation was enzymatically linked to this substrate
via K63 to generate SUMO-2-K63-(Ub)2. In the reaction, 300 mMubiquitin K63R and 100 mMhis-tagged SUMO-2-Ub were incubated
with 0.1 mM E1, 2.5 mM Ubc13, 2.5 mM and 0.55 mM RNF4RING at 20C overnight in a buffer containing 3 mM ATP, 5 mM MgCl2,
50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM TCEP and 0.1% (v/v) NP40. The reaction mixture was purified by Ni-NTA chroma-
tography. The Ni-NTA elution contained his-tagged SUMO-2-K63-(Ub)2 and his-tagged SUMO-2-Ub, which were separated on a
HiLoad Superdex 75 16/600 gel filtration column (ThermoFisher) in a buffer containing 50 mM Tris-HCl pH 7.5, 150 mM NaCl and
0.5 mM TCEP. Long K63-linked ubiquitin chains linked to tetra-SUMO were produced with the same method, using tetra-SUMO
and WT Ubiquitin. Reaction products were purified by size exclusion chromatography with a Superdex 200 16/200 gel filtration
column (ThermoFisher) and fractions containing chains larger than 100 kDa were pooled.
SUMO/Ubiquitin mixed chains degradation assay
Human BRCA1-A including full-length RAP80 (residues 1-719), or truncated RAP80 (residues 250-413) was prepared recombinantly
from insect cells. DUB reactions were started by mixing 1:1 BRCA1-A with the substrate (100 nM BRCA1-A was mixed with 2 mM
K63-diUb or SUMO-K63-diUb, and 20 nM BRCA1-A was mixed with 400 ng of Ubnub4xSUMO-2). Samples were taken at the
time points indicated and immediately mixedwith SDS-PAGE sample buffer (62.5mMTris-HCl pH 6.8, 2% (w/v) SDS, 25% (v/v) glyc-
erol, 0.05% (v/v) bromophenol blue, 5% (v/v) b-mercaptoethanol) in order to stop the DUB reaction. Samples were analyzed by SDS-
PAGE (Any kDMini-PROTEAN TGX Precast Protein Gel, Bio-Rad Laboratories) and subsequently visualized by staining with SYPRO
Ruby (Sigma-Aldrich). Stained gels were imaged with a Typhoon FLA 9500 imager (GE Healthcare Life Sciences). Band densitometry
was performed with Fiji (Schneider et al., 2012).
Protein expression and purification of BRCA1-BRCT
Qian Wu and Tom Blundell kindly provided the expression construct for the human BRCA1-BRCT domain (Wu et al., 2016).
BRCA1-BRCT was expressed recombinantly in E. coli BL21-CodonPlus (DE3)-RIL cells (Agilent Technologies). Cell pellets
were resuspended in lysis buffer containing 50 mM Tris-HCl pH 8.0, 200 mM NaCl, 0.1% Triton X-100, 1 mM PMSF, 0.2 mM
TCEP and Roche EDTA-free protease inhibitor (1 tablet per 500 ml) and lysed by sonication. After removal of cell debris by ultra-
centrifugation (45 min at 40,000g), the supernatant was filtrated through Miracloth (EMD Millipore) and subsequently applied to
Ni-NTA resin equilibrated with lysis buffer in a gravity flow column. The Ni-NTA resin was washed with wash buffer (50 mM
Tris-HCl pH 8.0, 200 mM NaCl, 0.2 mM TCEP) and bound protein was eluted by step gradient using wash buffer supplemented
with 10, 50, 200 and 500 mM imidazole, respectively. The eluate was concentrated by ultrafiltration (Amicon Ultra-15, 10 kDa mo-
lecular weight cutoff). Gel filtration with a Superdex 75was used to purify the protein and exchange the buffer to 50mMTris-HCl pH
8.0, 150 mM NaCl, 0.2 mM TCEP.
Sortase ligation of phosphorylated peptides to BRCA1-A
Phosphorylated versions of peptides from the C-terminal region of the BRCA1-A subunit ABRAXAS were covalently ligated to
BRCA1-A complex using the sortase ligation technique (Guimaraes et al., 2013). A modified human ABRAXAS expression construct
was designed adding a sortase recognition site followed by a FLAG tag at the C terminus (replacing the residues C-terminal of residue
I394 with the sequence LPETGDYKDHDGDYKDHDIDYKDDDDK). The FLAG tag allowed removal of unlabeled protein by affinity
chromatography and detection of successful labeling by SDS-PAGE (3.1 kDa decrease in protein mass). The modified human
ABRAXAS expression construct was synthesized (Integrated DNA Technologies) and cloned into a pFastBac expression vector.
BRCA1-A containing sortase-tagged ABRAXAS was expressed in insect cells and purified. Synthetic phosphorylated peptides
p-Ser404 (GGGFGEYpSRSPTF), p-Ser406 (GGGFGEYSRpSPTF) and p-Ser404/406 (GGGFGEYpSRpSPTF) (Biomatik) were dis-
solved in peptide buffer (20 mM Tris-HCl pH 8.0, 150 mMNaCl, 5 mMDTT) at 10 mg/ml and adjusted to pH 8.0. For sortase labeling,
a final concentration of 8.5 mM BRCA1-A in 50 mM HEPES pH 7.4, 200 mM NaCl, 0.2 mM TCEP), 870 mM peptide in peptide buffer,
and 20 mM sortase in 50 mM Tris-HCl, 200 mMNaCl, 10% (v/v) glycerol) were mixed to a final volume of 500 ml. Reactions were incu-
bated at 22C andmonitored for FLAG tag removal by SDS-PAGE analysis; reactions completed within 6 h. Sortase and excess pep-
tide were removed by gel filtration (Superose 6, ThermoFisher) in gel filtration buffer (50 mM HEPES pH 7.4, 150 mM NaCl, 0.2 mM
TCEP). Binding of BRCT to phosphorylated BRCA1-A was assessed by band shift in Coomassie Brilliant Blue-stained native PAGE
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Microscale thermophoresis binding assays
BRCA1-BRCT was labeled with the amine reactive RED-NHS labeling kit (NanoTemper Technologies). The labeled protein was pu-
rified by gel filtration over a Superdex 75 column (ThermoFisher) and diluted to 40 nM with assay buffer (50 mM HEPES pH 7.0,
100 mM NaCl, 0.5% BSA, 0.03% Brij-35, 0.2 mM TCEP). To determine the affinity of BRCA1-A p-Ser404/406 for BRCA1-BRCT,
BRCA1-A p-Ser404/406 at concentrations between 0 nM and 853 nM was mixed with 20 nM BRCA1-BRCT and non-labeled
BRCT in concentrations of 0 nM, 100 nM, 200 nM, 500 nM, 1000 nMwas added to replicates. After 10 min incubation at RT, samples
were loaded into Monolith NT.115 Premium capillaries (NanoTemper Technologies) and microscale thermophoresis was measured
using a Monolith NT.115 (NanoTemper Technologies). For the back-titration, 0-46.6 mM unlabeled BRCA1-BRCT was titrated into
200 nM BRCA1-A p-Ser404/406 and 20 nM labeled BRCA1-BRCT. Affinities were determined by global fit using DYNAFIT (Kuzmic,
2009).
Crosslinking mass spectrometry
The approximate position of BRCA1-BRCT in the BRCA1-A-BRCA1-BRCT complex was determined by crosslinking mass spec-
trometry of BRCA1-A p-Ser404/406 with BRCA1-BRCT.50 mg of BRCA1-A p-Ser404/406 was mixed with 20 mg BRCA1-BRCT in
a total volume of 117 ml. A 1 mg aliquot of the CID-cleavable DSSO crosslinking reagent (disuccinimidyl sulfoxide, MW = 388.35,
Spacer Arm = 10.3 A˚) was brought to room temperature and dissolved in 25 ml of anhydrous DMSO (100 mM stock). First the sample
buffer was transferred into a 100 kDa Amicon Ultra spin filter reactor (0.5 ml), followed by protein stock solution. Finally, the cross-
linking reagent was added and incubated at room temperature for 1 h. Excess of unreacted reagent was quenched by addition of
2.5 ml of 1M Tris (50 mM final conc.). After 50 min, filters were centrifuged for 2 min at 14000 g to remove crosslinking reagent
and non-crosslinked protein. Filters were topped off with 400 ml (max 450 ml) of 8 M urea in 50 mM HEPES pH 8.5 for denaturing
and washing, and then centrifuged for 2 min at 14000 g. This step was repeated twice. At the end of each spin, the sample was
concentrated to 40-50 ml. The sample was reduced and alkylated by addition of 5.5 ml of reduction/alkylation solution (stock:
50 mM TCEP, 100 mM 2-chloroacetamide, final concentration 5 mM TCEP and 10 mM 2-chloroacetamide) and subsequent incuba-
tion for 30 min in the dark. The samples were centrifuged for 2 min at 14000 g and topped-off with 50 mM HEPES pH 8.5, 8M urea,
centrifuged 2 min at 14000 g. This procedure was repeated twice for washing. The sample was digested by addition of 0.5 mg Lys-C
(5 ml of 0.1 mg/ml stock, 1:100 enzyme to protein ratio) and incubation for 4 h at room temperature. The Lys-C digest was diluted 4-fold
by addition of 240 ml of 50 ml HEPES pH 8.5 followed by addition of 0.5 mg of trypsin (2.5 ml of 0.2 mg/ml stock, 1:100 enzyme to protein
ratio) and digestion overnight. Next, the sample was incubated for four h after addition of an additional aliquot of 0.5 mg of trypsin
(1:100) and 35 ml of acetonitrile to a final concentration of 10%. The filter containing the trypsin digest was inverted and spun
1 min at 1000 g to collect the digest into a fresh Eppendorf tube. The digest was acidified with TFA to 1% final concentration,
then sonicated, and centrifuged for 5 min at 20000 g. LC-MS analysis was performed using a 2 cm trapping column and a 50 cm
analytical column coupled to an Orbitrap Fusion LUMOS mass spectrometer using a 90 h gradient and the MS2_MS3 method.
Bio-layer interferometry
Affinity between BRISC and SHMT2 was measured by bio-layer interferometry with BRISC immobilized on the sensor and SHMT2 in
solution. BRISC was expressed with a Strep-BirA tag fused to the N terminus of ABRO1. The reaction mixture of 1 ml BirA-BRISC
(4.6 mg/ml), 60 ml BirA enzyme (2.4 mg/ml), 20 ml 1 M MgCl2, 200 ml 2 mM biotin, 100 ml 400 mM ATP pH 7.5 was adjusted to a final
volume of 1.5 ml by addition of 620 ml phosphate buffered saline (PBS), incubated at RT for 1 h, and subsequently at 4C overnight.
Biotinylated BRISC complex was purified by gel filtration (Superdex 200, ThermoFisher). Association and dissociation constants
were measured in BLI buffer (50 mMHEPES pH 7.4, 100 mMNaCl, 0.2 mM TECP, 2mg/ml BSA) with a BLItz bio-layer interferometer
using Streptavidin-coated sensors (Forte´Bio).
Internally quenched fluorophore (IQF) deubiquitination assays
Cleavage of K63-diUb was measured using an internally quenched (Ub)2 substrate, which carries a fluorophore (TAMRA) on one
ubiquitin molecule and a quencher on the other. Following DUB cleavage of the K63 isopeptide bond, a quencher-bound ubiquitin
is released and TAMRA fluorescence increases. BRISC activity was tested against six available fluorophore/quencher positions
(DU0102, LifeSensors) and compared to cleavage of unlabeled (Ub)2 in a gel-based assay. Subsequent DUB activity assays were
performed with linkage type 1 substrate (DU6301, LifeSensors). The deubiquitination reactions were initiated bymixing 5 ml of protein
in storage buffer (50 mMHEPES pH 7.4, 200 mMNaCl, 0.2 mM TCEP) with 5 ml of substrate at 400 nM (200 nM final concentration) in
assay buffer (50 mM HEPES pH 7.0, 100 mM NaCl, 0.5% BSA, 0.03% Brij-35, 0.2 mM TCEP). Fluorescence was monitored in 10 s
time increments (excitation at 540 nm, emission at 590 nm) and molar reaction rates were determined by comparison to TAMRA-
ubiquitin (SI270T, LifeSensors) controls. Assays were carried out at 22C in black flat-bottom high-base 386-well plates (Greiner
Bio-One) using a Pherastar plate reader (BMG Labtech). Reaction progress data were fitted globally with DYNAFIT (Kuzmic, 2009).
Quantitative fluorescence microscopy of ABRO1 and SHMT2
HEK293T cells were grown in DMEM supplemented with 10% (v/v) FBS on glass coverslips in six-well dishes for 48 h. For mitochon-
drial labeling, 100 nM MitoTracker Red CMXRos (ThermoFisher) was added to media and cells were incubated for 30 min at 37C.
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membranes were then labeled with 5 mg/ml Alexa Fluor 633-conjugated wheat germ agglutinin (ThermoFisher) for 10 min at RT. Cells
were subsequently washed three times with PBS, permeabilized for 15 min at RT in PBS supplemented with 0.2% (v/v) Triton X-100,
then blocked for 1 h in PBS supplemented with 10% (v/v) donkey serum and 2% (w/v) BSA. Samples were incubated overnight at 4C
in a humid chamber with primary antibodies diluted in blocking solution (Rabbit anti-SHMT2 (SAB1100388, Sigma-Aldrich, 1:200);
Rabbit anti-ABRO1 (ab74333, abcam, 1:100). Samples were washed in PBS then incubated overnight at 4C with an Alexa Fluor
488-conjugated donkey anti-rabbit antibody (Sigma-Aldrich, 1:500). Sampleswerewashedwith PBS andmountedwith VectorShield
with DAPI (VectorLabs) and sealed with nail polish. Slides were imaged with a W1 Spinning-Disk (Yokogawa) mounted on an Axio
Imager Z2 microscope (Zeiss) and controlled with VISIVIEW (Visitron). Fluorescence quantification in the different cell compartments
was carried out with FIJI (Schindelin et al., 2012) on 3D Z stacks as follows: signal was smoothed with a Gaussian filter in all channels;
masks for the nuclei and the mitochondria were generated using the DAPI and MitoTracker channels respectively, applying auto-
threshold with theOtsu orMomentsmethods after background subtraction (rolling ball). The same treatment was applied to the Alexa
Fluor 488 channel and the resulting image was combined with the masks for nuclei and mitochondria to create a mask for the whole
cell; these threemaskswere then used to quantify in each plane the amount of fluorescence in the Alexa Fluor 488 channel (SHMT2 or
ABRO1 staining).
QUANTIFICATION AND STATISTICAL ANALYSIS
Assays were conducted at least in triplicate, with SD reported, with the exception of experiments that were conducted as dilution
replicates and fitted globally. Sample size was not determined a priori.
DATA AND SOFTWARE AVAILABILITY
The accession number for the crystal structure of BRCA1-A reported in this paper is PDB: 6GVW. The accession number for the cryo-
EM density map of BRISC-SHMT2a complex reported in this paper is EMDB: EMDB-0132. The accession number for the model of
BRISC-SHMT2a complex reported in this paper is PDB: 6H3C. The link for access to raw imaging data reported in this paper is Men-
deley Data: https://dx.doi.org/10.17632/8ntswhp8d5.1.e9 Molecular Cell 75, 483–497.e1–e9, August 8, 2019
